Fenbendazole 222mg Capsules For Humans
Fenbendazole is a commonly used antihelminthic drug. It has been shown to have cytotoxic and antitumor activities in cell culture and in mice with EMT6 mammary carcinoma tumors, but these effects are not demonstrated in the presence of radiation or other chemotherapy agents. It has also been found to have a number of other potential therapeutic properties, and its mechanisms of action are thought to overlap with those of hypoxia-selective nitroheterocyclic cytotoxins/radiosensitizers, the taxanes and vinca alkaloids.
We used a model of subcutaneous flank implantation of 3 x 107 lymphoma cells, and compared tumor growth in untreated control mice with that of the same group receiving three daily injections of fenbendazole plus local tumor irradiation. Tumor volume was measured at 4-d intervals until tumors reached a calculated volume of 1500 mm3 (Table I). Fenbendazole alone did not affect the growth of these tumors or significantly alter the effect of irradiation, even in the absence of other drugs. However, when fenbendazole was combined with vitamin-enriched diets, there was a marked decrease in the rate of tumor growth, and radiation was more effective. The initial complete blood count in each treatment group was similar to those of SCID mice, demonstrating low numbers of white cells and a paucity of lymphocytes.
We speculate that the less dramatic effect initially observed in this study may have been due to the fact that the diet containing both vitamins and fenbendazole was nearing its expiration date (approximately 6 mo after manufacture) at the time of the first observation, resulting in lower vitamin concentrations than in the diet used during the initial experiment. Nevertheless, the results of this study demonstrate that the combination of fenbendazole and vitamins significantly inhibited the growth of these tumors, a finding that deserves further investigation.